Drug Research

Bristol-Myers Squibb Company announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) (F1-F3). ...

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. ...

IBM announced that its scientists have been granted a patent on machine learning models to predict therapeutic indications and side effects from various drug information sources. IBM Research has implemented a cognitive association engine to identify...

Pharnext SA , a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases announced a research and development (R&D) agreement with Galapagos NV. The main goal of this agreement is...

Titan Pharmaceuticals, Inc ,a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform announced that the U.S. FDA has completed its initial review of the ropinirole implant Investigational New...

Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6) receptor antibody. For the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate...

University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes....